DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



To Assess the Safety and Tolerability of 7.5, 15 and 30 mg of Sublingual Lobeline. - 1

Information source: National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Amphetamine-Related Disorders

Intervention: Lobeline (Drug)

Phase: Phase 1

Status: Active, not recruiting

Sponsored by: National Institute on Drug Abuse (NIDA)

Official(s) and/or principal investigator(s):
Reese Jones, M.D., Principal Investigator, Affiliation: Langley Porter Psychiatric Institute

Summary

To assess the safety and tolerability of 7. 5, 15 and 30 mg of sublingual lobeline.

Clinical Details

Official title: Safety and Tolerability Study of Sublingual Lobeline

Study design: Primary Purpose: Diagnostic

Primary outcome: Safety

Detailed description: The primary objective of this study is to characterize the pharmacokinetics of three ascending doses of lobeline in normal volunteers.

Eligibility

Minimum age: 18 Years. Maximum age: 45 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Healthy individuals with a body mass index between 18 and 30.

- Willing and able to give written consent.

- Must have a negative drug test

- Females must have a negative pregnancy test prior to study drug administration

- Must have no medical contraindications as determined by routine testing

Exclusion Criteria:

- Please contact the site for more information

Locations and Contacts

U of CA, San Francisco, San Francisco, California 94143, United States
Additional Information

Starting date: September 2004
Last updated: October 25, 2007

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017